Dafinchi AI

AMGN

Healthcare

15 products achieved double-digit sales growth, highlighting portfolio strength.
Amgen reported Q2 2025 revenues of $9.2 billion, a 9% year-over-year increase driven by 13% volume growth.
Dividend payments increased by 6% to $2.38 per share compared to Q2 2024.
Free cash flow was $1.9 billion, supporting continued innovation investments.
Non-GAAP operating expenses rose 8%, with R&D up 18% reflecting investments in late-stage pipeline programs.
Non-GAAP operating income and expenses (OI&E) improved by $213 million year-over-year due to debt retirement and lower interest expense.

MNKD

Healthcare

Afrezza net revenues increased 13% to $18 million in Q2, driven by growth in new and recurring prescriptions.
Collaboration and services revenue declined 12% to $23 million due to timing of manufacturing and one-time items.
Q2 2025 revenues reached $77 million, a 6% increase over Q2 2024, with year-to-date revenues of $155 million, up 12% from 2024.
The company ended Q2 with a strong cash position of $201 million and secured up to $500 million in nondilutive capital from Blackstone.
Tyvaso DPI royalties grew 22% year-over-year to $31 million in Q2, contributing significantly to revenue growth.
V-Go net revenue decreased 8% to approximately $4 million, reflecting lower product demand and lack of active promotion.

Earnings Feed